What Is Cagrilintide?

What cagrilintide is

Cagrilintide is a synthetic, long-acting amylin analog developed by Novo Nordisk for the treatment of overweight and obesity. In plain terms, it’s a lab-engineered version of a natural hormone called amylin — redesigned so that a single subcutaneous injection keeps working for about a week.

The single most important thing to understand about cagrilintide is what it is not. It is not a GLP-1 drug like semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound). Those medications get most of the attention, and people often assume cagrilintide is “another one of those.” It isn’t. It works on a different hormone system entirely, which is precisely why the two are being combined rather than pitted against each other.

It’s also not, as of 2026, something you can walk into a clinic and get. Cagrilintide is an investigational compound. Its real-world significance comes almost entirely from the combination product it’s part of — CagriSema — covered throughout below.

Note: This page is the foundational explainer for cagrilintide — what the molecule is and where it sits in the obesity-drug landscape. Sibling pages go deeper on specific angles: see the benefits, weight-loss, cost, and side-effect pages linked above for those.

The hormone behind it: amylin

To understand cagrilintide you have to understand amylin. Amylin is a hormone secreted by the same pancreatic beta cells that make insulin, and it’s released alongside insulin every time you eat. Its job is part of the body’s natural “stop eating” system. Amylin slows how fast the stomach empties, dampens appetite, and signals fullness to the brain.

In many people with obesity or metabolic dysfunction, that amylin signaling is blunted — the body’s built-in brake on eating doesn’t engage the way it should. Natural amylin also breaks down very quickly in the body, which makes the hormone itself useless as a once-weekly medicine.

Cagrilintide is the engineering answer to both problems. It’s an amylin analog: a modified molecule that activates the same receptors amylin does, but is chemically stabilized so it lasts far longer in circulation. That’s what makes a once-weekly injection feasible. (An older, shorter-acting amylin analog, pramlintide, already exists and is used in diabetes — but it has to be injected multiple times a day, which is part of why cagrilintide drew so much interest.)

How it differs from GLP-1 drugs

This is the distinction that matters most, and it’s where a lot of confusion lives.

GLP-1 receptor agonists — semaglutide, tirzepatide, and the like — act on the GLP-1 pathway (and, in tirzepatide’s case, GIP as well). Cagrilintide acts on the amylin pathway. Both pathways influence appetite and fullness, but they do it through distinct receptors and brain regions. They are complementary brakes, not the same brake.

That complementarity is the entire strategic point. Because amylin and GLP-1 work through separate mechanisms, hitting both at once can produce a larger combined effect than maxing out either one alone. This is why Novo Nordisk’s flagship program isn’t “cagrilintide vs. semaglutide” — it’s cagrilintide plus semaglutide, in a single fixed-dose injection.

So when you see cagrilintide framed as a “next-generation weight-loss drug,” the accurate reading is: it’s a next-generation component. Its value proposition is additive.

The real story: CagriSema

Cagrilintide’s development has converged almost entirely on CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg given as one once-weekly subcutaneous injection. When people talk about cagrilintide’s impressive trial numbers, they are nearly always talking about CagriSema.

In the Phase 3 REDEFINE 1 trial — roughly 3,400 adults with obesity, or overweight with a related complication — CagriSema produced an average weight loss of around 20-23% over 68 weeks, depending on which statistical estimand is used (the higher figure reflects an idealized scenario in which everyone stayed on treatment). A large majority of participants achieved at least 5% weight loss, and a substantial share crossed the 20% and even 30% thresholds. Those are among the strongest results reported in obesity pharmacotherapy to date.

The contrast with cagrilintide alone is instructive. In its earlier Phase 2 monotherapy trial (published in The Lancet in 2021), standalone cagrilintide produced roughly 10-11% weight loss over about 26 weeks — meaningful, but not category-defining on its own. Trial comparisons have generally placed cagrilintide-alone below semaglutide-alone, with the combination clearly out in front of both. That gap is the whole reason the program is built around the combination rather than the single agent.

In December 2025, Novo Nordisk submitted a New Drug Application to the FDA for CagriSema for weight management, with FDA review expected during 2026. A separate development program (REIMAGINE) is studying CagriSema in type 2 diabetes.

Its US status in 2026

Here is the bottom line on access, stated plainly:

Cagrilintide is not FDA-approved for any indication as of 2026. It is investigational. There is no approved standalone cagrilintide product, and — critically — no compounding pathway for it either. That last point trips people up. With some peptides, “not FDA-approved” still leaves a 503A compounding route open under specific conditions. Cagrilintide does not have that. A licensed provider cannot legally prescribe or compound standalone cagrilintide through normal pharmacy channels.

The only legitimate way to receive cagrilintide right now is enrollment in an active clinical trial running it. Outside of that, there is no compliant route to standalone cagrilintide in the US.

CagriSema, the combination, is the product working through the approval system — but it too is not yet approved, so it isn’t available by prescription either while the FDA review is pending. If and when CagriSema is approved, that would be the realistic route to cagrilintide reaching patients: as the amylin half of an approved combination, not as a drug sold on its own.

Note: Regulatory status moves fast in this space. Everything here is current as of the date at the top of this page and can change — especially as the CagriSema FDA review progresses during 2026. Treat dated claims accordingly.

The gray-market caveat

Because cagrilintide’s trial numbers have been widely publicized, the name circulates in “research peptide” and gray-market channels, sometimes sold standalone as a vial of powder. This is worth flagging directly.

Products sold this way are unregulated. The actual contents, concentration, and purity of a gray-market vial are not verified by any authority, and a name on a label is not a guarantee of what’s inside. Cagrilintide is an injectable, which raises the stakes considerably compared with an oral supplement. The fact that a compound performed well in a controlled clinical trial — under medical supervision, with a verified pharmaceutical-grade product — tells you very little about the safety of an unverified vial bought online and self-administered.

This site is educational and does not cover sourcing or self-administration. For how legitimate access is meant to work — the legal routes, and why the standard channels come up empty for an investigational compound — see the access pages linked below.

Where cagrilintide fits in the bigger picture

Cagrilintide is best understood as part of a broader shift in obesity medicine away from single-mechanism drugs and toward combination and multi-target approaches. Tirzepatide already combines two pathways (GLP-1 and GIP) in one molecule. Retatrutide, another investigational compound, targets three. CagriSema takes the pairing route — two separate engineered hormones in one shot, hitting GLP-1 and amylin together.

For a reader trying to orient: if you’re researching cagrilintide because you saw the weight-loss headlines, the practical takeaway is that the headline drug is CagriSema, not cagrilintide by itself, and neither is something you can obtain through a legitimate channel in 2026 yet. The most useful next step is understanding the combination and its status rather than chasing the standalone molecule.

Key points

• Cagrilintide is a long-acting amylin analog, not a GLP-1 drug. It works on a different hormone system, which is why it’s combined with semaglutide rather than competing with it.
• Amylin is a natural fullness hormone released with insulin; cagrilintide is an engineered, stabilized version designed for once-weekly dosing.
• The strong weight-loss numbers belong to CagriSema (the cagrilintide + semaglutide combination), not to cagrilintide alone — standalone cagrilintide produced roughly 10-11% in Phase 2, versus around 20%+ for the combination in REDEFINE 1.
• As of 2026, cagrilintide is not FDA-approved, has no compounding pathway, and is not available standalone through any legitimate route; CagriSema is under FDA review but not yet approved.
• Gray-market standalone cagrilintide is unregulated and unverified — a clinical-trial result does not transfer to an unverified vial.